Premium
Combined immunosuppressants and less steroids in active graves' orbitopathy?
Author(s) -
Salvi Mario,
Covelli Danila
Publication year - 2019
Publication title -
clinical endocrinology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.055
H-Index - 147
eISSN - 1365-2265
pISSN - 0300-0664
DOI - 10.1111/cen.13917
Subject(s) - medicine , adverse effect , steroid , randomized controlled trial , endocrinology , clinical trial , hormone
Steroid therapy in GO is first‐line treatment but has limitations, as it is potentially harmful at high doses and often refused by patients. A steroid‐sparing therapy is a reasonable option as long as it is rapidly effective and devoid of long‐term adverse reactions. Combined immunosuppressive therapy must be studied in randomized clinical trials designed to test efficacy and the potentially increased risk of side effects.